Metastatic Colorectal Cancer
Conditions
Keywords
bevacizumab, overall survival, adverse events, tumor resection rate
Brief summary
This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.
Interventions
DRUGBevacizumab
Sponsors
Peking University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* histologically confirmed metastatic colorectal cancer patients Having initiated treatment with bevacizumab
Exclusion criteria
* non-metastatic colorectal cancer patients not recieved bevacizumab
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | 6 weeks | To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 3 months | OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost |
| progression free survival | 6 weeks | the follow-up visit of PFS will be performed every 6 weeks |
| Proportion of patients with bevacizumab treatment discontinuation | 3 weeks | Proportion of patients with bevacizumab treatment discontinuation due to bevacizumab-related adverse events |
| resection rate | 1 month | resection rate of tumor after chemotherapy plus bevacizumab |
Countries
China
Contacts
Primary ContactLin Shen, M.D.
Backup ContactJifang Gong, M.D.
Outcome results
None listed